- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 13/00 - Drugs for disorders of the urinary system
Patent holdings for IPC class A61P 13/00
Total number of patents in this class: 1031
10-year publication summary
42
|
45
|
37
|
43
|
58
|
65
|
84
|
55
|
69
|
11
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Bayer AG | 3045 |
27 |
Bayer Pharma AG | 1096 |
23 |
Astellas Pharma Inc. | 1145 |
21 |
F. Hoffmann-La Roche AG | 7958 |
19 |
Janssen Pharmaceutica N.V. | 3839 |
18 |
Allergan, Inc. | 2600 |
18 |
Takeda Pharmaceutical Company Limited | 2961 |
16 |
Ranbaxy Laboratories Limited | 453 |
15 |
Shionogi & Co., Ltd. | 914 |
12 |
Teva Pharmaceuticals USA, Inc. | 1040 |
10 |
Novartis AG | 11238 |
9 |
Boehringer Ingelheim International GmbH | 4629 |
9 |
Bayer Healthcare AG | 271 |
9 |
Bristol-myers Squibb Company | 5080 |
8 |
Teva Pharmaceutical Industries Ltd. | 868 |
8 |
Santa Farma İlaç Sanayi̇ A.ş. | 40 |
8 |
Vertex Pharmaceuticals Incorporated | 1581 |
7 |
Angion Biomedica Corp. | 74 |
7 |
sanofi-aventis | 427 |
7 |
The Procter & Gamble Company | 22178 |
6 |
Other owners | 774 |